| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2010 | CA2734037A1 Pyrimidinyl pyridone inhibitors of jnk |
| 04/29/2010 | CA2728949A1 Thiophene containing analogues of fluconazole as antifungal agents and process thereof |
| 04/29/2010 | CA2684157A1 Compositions incorporating agents for reducing cellulite and unaesthetic appearance associated therewith and formulations containing them |
| 04/28/2010 | EP2179999A1 Fused tricyclic compound having aldose reductase inhibitory activity |
| 04/28/2010 | EP2179998A1 2-(2-oxoindoline-3-ylidene)methyl-5-(2-hydroxy-3-morpholin-4-yl -propyl)-6,7-dihydro -1h- pyrrol[3,2-c]pyridine-4(5h)-one compounds and use as protein kinase inhibitors |
| 04/28/2010 | EP2179997A1 Sulfonamide compound, and crystal thereof |
| 04/28/2010 | EP2179994A1 Fused bicyclic compound |
| 04/28/2010 | EP2179993A1 Sulfoxide substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179992A1 Sulfon substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179991A1 Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine |
| 04/28/2010 | EP2179989A2 Process for the preparation of heteroaryl - aryl ether |
| 04/28/2010 | EP2179987A2 Anti-sickling agents |
| 04/28/2010 | EP2179986A1 Mixtures of alkylsulfosuccinates and their use |
| 04/28/2010 | EP2179984A1 Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
| 04/28/2010 | EP2179982A2 Method for producing mechanically activated amorphous and amorphocrystalline compounds of gluconic acid calcium salt |
| 04/28/2010 | EP2179745A1 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2010 | EP2179739A1 Compositions comprising vitamins |
| 04/28/2010 | EP2179737A2 Modulating responsiveness to steroids |
| 04/28/2010 | EP2179736A1 Two-component eye drops containing pirenoxine |
| 04/28/2010 | EP2179735A1 Pharmaceutical composition combining lamotrigine and clonazepam, and use thereof for treating convulsive disorders and epileptic syndromes |
| 04/28/2010 | EP2179734A1 Benzoxazine and dihydroquinazoline derivatives for use in the treatment of alcohol withdrawal syndrome |
| 04/28/2010 | EP2179733A1 Pharmaceutical composition combining an antimicrobial agent and a selective enkephalinase enzyme inhibitor, which can be used to control and treat acute bacterial diarrhoea |
| 04/28/2010 | EP2179732A1 Pharmaceutical composition combining an enzyme hmg-coa reductase inhibiting agent and a gastrointestinal lipase enzyme inhibiting agent |
| 04/28/2010 | EP2179731A1 Amino-acid-containing medicinal granular preparation highly easy to take |
| 04/28/2010 | EP2179730A1 Pharmaceuticals and methods for treating hypoxia and screening methods therefor |
| 04/28/2010 | EP2179726A2 Dietary fiber inulin delivery system |
| 04/28/2010 | EP2179725A1 Pharmaceutical composition comprising levetiracetam |
| 04/28/2010 | EP2179724A2 Tamper-resistant products for opioid delivery |
| 04/28/2010 | EP2179661A1 Biscuit comprising guar gum in a rod-like form |
| 04/28/2010 | EP2179660A2 Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids |
| 04/28/2010 | EP2179286A2 Trim24 (tif1a) as p53 modulator and cancer target |
| 04/28/2010 | EP2179284A2 Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function |
| 04/28/2010 | EP2179040A2 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis |
| 04/28/2010 | EP2179039A2 Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles |
| 04/28/2010 | EP2178902A1 Macrocyclic compounds as antiviral agents |
| 04/28/2010 | EP2178899A1 17beta-cyano-18a-homo-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative |
| 04/28/2010 | EP2178888A1 Proteasome inhibitors |
| 04/28/2010 | EP2178886A1 Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| 04/28/2010 | EP2178885A1 Macrocyclic indole derivatives for the treatment of hepatitis c infections |
| 04/28/2010 | EP2178882A1 Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| 04/28/2010 | EP2178881A2 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors |
| 04/28/2010 | EP2178879A2 6-cycloamino-s-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof |
| 04/28/2010 | EP2178878A1 Tetracyclic compounds for the treatment of hepatitis c |
| 04/28/2010 | EP2178877A1 Anti-viral compounds, compositions, and methods of use |
| 04/28/2010 | EP2178876A1 Spiro condensed barbituric acid derivatives for use as antibacterial |
| 04/28/2010 | EP2178875A1 Indolopyridines as inhibitors of the kinesin spindle protein (eg5 ) |
| 04/28/2010 | EP2178874A1 Heterocyclic compounds useful as mk2 inhibitors |
| 04/28/2010 | EP2178873A1 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile derivatives as cathepsin inhibitors |
| 04/28/2010 | EP2178872A1 Paliperidone derivatives |
| 04/28/2010 | EP2178871A2 Cyclic ethers |
| 04/28/2010 | EP2178868A1 Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| 04/28/2010 | EP2178866A2 Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| 04/28/2010 | EP2178858A1 Novel heterocyclic compounds as mglu5 antagonists |
| 04/28/2010 | EP2178854A1 Lejimalid analoga and uses thereof |
| 04/28/2010 | EP2178852A1 Alkylsulfonyl-substituted thiazolide compounds |
| 04/28/2010 | EP2178851A1 Compounds and methods for modulating fxr |
| 04/28/2010 | EP2178850A1 Trazodone and trazodone hydrochloride in purified form |
| 04/28/2010 | EP2178849A1 Integrated photoactive agents and uses thereof |
| 04/28/2010 | EP2178845A2 Inhibitors of 11b-hydroxysteroid dehydrogenase |
| 04/28/2010 | EP2178844A1 Azepine derivatives as gamma-secretase inhibitors |
| 04/28/2010 | EP2178842A2 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use |
| 04/28/2010 | EP2178840A1 Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors |
| 04/28/2010 | EP2178839A2 New anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution |
| 04/28/2010 | EP2178838A2 New thrombin function compounds and pharmaceutical compositions based on them |
| 04/28/2010 | EP2178835A1 Novel substituted piperidones as hsp inducers |
| 04/28/2010 | EP2178834A1 Three-functional pseudo-peptidic reagent, and uses and applications thereof |
| 04/28/2010 | EP2178830A2 Novel compounds |
| 04/28/2010 | EP2178827A1 Crystalline solid forms |
| 04/28/2010 | EP2178825A1 Method for the synthesis of a-ring aromatized acetyl minocyclines |
| 04/28/2010 | EP2178824A1 Amino acid derivatives |
| 04/28/2010 | EP2178823A1 Spiro cyclopentane compounds useful as antagonists of the h1-receptor |
| 04/28/2010 | EP2178818A2 Treatments using vitamin k analogues and derivatives |
| 04/28/2010 | EP2178567A2 Stabilized immune modulatory rna (simra) compounds |
| 04/28/2010 | EP2178564A1 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye |
| 04/28/2010 | EP2178562A1 Synergistic combinations of vr-1 antagonists and cox-2 inhibitors |
| 04/28/2010 | EP2178555A1 Albumin for treating cancer and a pharmaceutical composition comprising the combination of an anti-neoplastic agent and albumin |
| 04/28/2010 | EP2178540A1 Pharmaceutical composition suitable for adsorption to the cell surface of pathogenic microbes |
| 04/28/2010 | EP2178537A1 Beta carboline derivatives as antidiabetic compounds |
| 04/28/2010 | EP2178536A1 Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein |
| 04/28/2010 | EP2178535A1 Compositions and methods for modulating endophthalmitis using fluoroquinolones |
| 04/28/2010 | EP2178534A1 Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| 04/28/2010 | EP2178533A1 Antiviral composition comprising a sulfated polysaccharide |
| 04/28/2010 | EP2178532A2 Anti-bacterial drug targeting of genome maintenance interfaces |
| 04/28/2010 | EP2178528A1 Stabilized tolterodine tartrate formulations |
| 04/28/2010 | EP2178527A1 Method for activating regulatory t-cells |
| 04/28/2010 | EP2178526A1 Injectable pharmaceutical compositions containing panthenol |
| 04/28/2010 | EP2178525A1 Resveratrol complex and process for the preperation |
| 04/28/2010 | EP2178523A2 Transdermal therapeutic systems which contain the substance anastrozole |
| 04/28/2010 | EP2178522A1 Compressed chewing gum tablet comprising taste-masking agent |
| 04/28/2010 | EP2178521A1 Stable medicated chewing gum comprising cyclodextrin inclusion complex |
| 04/28/2010 | EP2178520A1 Drug formulations having inert sealed cores |
| 04/28/2010 | EP2178516A2 Pharmaceutical composition comprising 11-deoxy-prostaglandin compound and method for stabilizing the compound |
| 04/28/2010 | EP2178515A2 Stable compositions |
| 04/28/2010 | EP2178510A2 Stable solid pharmaceutical composition comprising candesartan or pharmaceutically acceptable forms thereof |
| 04/28/2010 | EP2178508A1 Stable formulations of thiadiazole derivatiive |
| 04/28/2010 | EP2178506A1 Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics |
| 04/28/2010 | EP2178504A2 Preservative-free prostaglandin-based ophthalmic solution |
| 04/28/2010 | EP2178503A1 Oral pharmaceutical solutions containing telbivudine |
| 04/28/2010 | EP2178502A2 Sustained delivery of drugs from biodegradable polymeric microparticles |
| 04/28/2010 | EP2178486A2 Packaging kit for statins and compositions thereof |